نتائج البحث - Michael Teufel

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma

    Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma حسب Michael Teufel, Henrik Seidel, Karl Köchert, Gerold Meinhardt, Richard S. Finn, Josep M. Llovet, Jordi Bruix

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA.

    Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA. حسب Utz Fischer, Sylvie C. Meyer, Michael Teufel, Cecile Dupin de Saint Cyr - Heckel, Reinhard Lührmann, G Rautmann

    منشور في 1994
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

    Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma حسب Maria Kissel, Sandra Berndt, Lukas Fiebig, Simon Kling, Qunsheng Ji, Qingyang Gu, Tina Lang, Frank‐Thorsten Hafner, Michael Teufel, Dieter Zopf

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors

    Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors حسب Changhoon Yoo, Ángela Lamarca, Hye Jin Choi, Arndt Vogel, Michael J. Pishvaian, Lipika Goyal, Makoto Ueno, Angela Märten, Michael Teufel, Lijiang Geng, Chigusa Morizane

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series حسب Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Patricia LoRusso

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

    The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study حسب Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M. Gounder

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

    Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospecti... حسب Josep Tabernero, Heinz‐Josef Lenz, Salvatore Siena, Alberto Sobrero, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Takayuki Yoshino, Richard M. Goldberg, Daniel J. Sargent, Thierry André, Dirk Laurent, Michael Teufel, Michael Jeffers, Axel Grothey, Eric Van Cutsem

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma

    Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma حسب Ho Yeong Lim, Philippe Merle, Karl Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean‐Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gerolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Katrin Roth, Diego Reis, Barrett H. Childs, Heiko Krissel, Josep M. Llovet

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: